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Studies demonstrating the negative impact of paediat-
ric psoriasis on health-related quality of life (HRQOL) 
are accumulating, but little is known about modera-
tors of HRQOL. The objectives of this review were to 
summarize studies on HRQOL in paediatric psoriasis 
and to explore the potential moderating influences 
of demographic and clinical variables. Searches were 
conducted by 2 independent researchers in PubMed, 
Embase, CINAHL, PsycINFO, and Scopus for papers 
published between 1995 (the date the first derma-
tology-specific HRQOL-instrument for children was 
introduced) and 2016. Eligible studies were required 
to report HRQOL data for children and/or adolescents 
with psoriasis (4–18 years) using validated HRQOL 
questionnaires. Seven teen eligible studies (number of 
patients = 1,185) were identified. Moderation analyses 
revealed that study samples with a higher percentage 
of girls were associated with better HRQOL (β = 0.19), 
while a higher mean age of onset (β = 0.83) and study 
quality (β = 0.28) were associated with lower HRQOL 
(all p<0.05). Several papers did not provide the infor-
mation necessary for exploring between-study differ-
ences, thus the moderation analysis results should be 
interpreted with caution. In conclusion, children and 
adolescents with psoriasis experience moderate im-
pairment of HRQOL. Certain demographic characteris-
tics (e.g. sex) and clinical characteristics (e.g. age at 
onset) appear to moderate this impact.
Key words: psoriasis; health-related quality of life; children; 
adolescents; systematic review; meta-analysis.
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Psoriasis is a common chronic inflammatory skin di-sease with a prevalence of 2–3% in Western countries 
(1–3). It is estimated that 0.7–1.2% of all children suffer 
from psoriasis (3, 4), with one-third of patients being 
diagnosed by the age of 20 years (2). Although psoriasis 
may take various clinical forms, the majority of children 
present with either plaque psoriasis (71%) or guttate 
psoriasis (26%) (5).
A European consensus report suggests that patients 
with psoriasis are both undertreated and underserved 
(6). Increased emphasis on patients’ overall evaluation 
of disease impact was identified as a major step towards 
better treatment for patients. Reviews of studies on 
functioning in adult psoriasis have shown increased 
rates of comorbid mental disorders, especially anxiety 
and depression, in addition to a range of psychosocial 
problems, such as poor self-esteem, social stigmati-
zation, physical limitations, sexual dysfunction, and 
suicidal ideations (7, 8). Although paediatric patients 
have received far less research attention, a large study 
comparing paediatric patients with psoriasis (n = 7,404) 
with psoriasis-free control subjects (n = 37,020), also 
found a higher prevalence of depression and anxiety in 
paediatric patients (9). Identifying the optimal treatment 
for psoriasis can be a lengthy process, and the treatments 
can be burdensome, time-consuming, and associated 
with considerable side-effects (10, 11). This may further 
challenge patients’ well-being, especially in children who 
might lack a thorough understanding of the importance 
of treatment. Qualitative studies have also identified a 
number of psychosocial challenges in the daily lives of 
children with psoriasis (12, 13).
In recent decades, studies have shed light on patients’ 
subjective experiences of medical diseases and their 
impact on patient’s life, as captured by the construct of 
health-related quality of life (HRQOL) (14). Although 
operational definitions vary, HRQOL is generally con-
ceptualized as a multidimensional construct reflecting 
patients’ physical, psychological, and social well-being 
(15–17). HRQOL can be measured using generic or 
disease-specific questionnaires. Generic instruments 
have been constructed to apply to healthy individuals 
as well as people with medical issues, whereas disease-
specific instruments are tailored to specific populations 
with a given disease or symptom and thus tend to be 
more sensitive (15). Research on the association bet-
ween psoriasis-related HRQOL and clinical measures 
of disease severity, e.g. the Psoriasis Area and Severity 
Index (PASI) (18), generally show modest correlations 
(19), indicating that the traditional measures of disease 
severity do not fully capture the impact of psoriasis on 
well-being. It is thus widely accepted that psoriasis treat-
ment should aim not only at minimizing the extent and 
severity of psoriasis, but also at reducing the negative 
impact on patients’ HRQOL (6, 20, 21). 
In 2004, de Korte et al. (22) published a systema-
tic review of 17 studies on HRQOL in patients with 
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psoriasis (mean age 47 years). Authors reported that 
patients experienced physical discomfort, impaired 
emotional functioning, negative body- and self-image, 
and limitations in daily activities, social contacts, (skin-
exposing) activities, and work. However, they noted 
that the studies were highly heterogeneous, making 
between-study comparison difficult. Recently, Olsen et 
al. (23) published a systematic review and meta-analysis 
of HRQOL studies using the Children’s Dermatology 
Life Quality Index (CDLQI) across a broad range of 
paediatric skin diseases. Based on data from 67 studies, 
the authors concluded that the overall mean effect of skin 
disease on HRQOL in children is small. Comparative 
analyses showed that patients in the psoriasis subgroup 
(5 studies, comprising 279 patients) experienced small-
to-moderate impairment of HRQOL, although results for 
this subgroup should be interpreted with caution due to 
wide confidence intervals. 
To the best of our knowledge, no systematic review 
evaluating HRQOL in paediatric psoriasis based on the 
full range of available HRQOL instruments has yet been 
published. Furthermore, little is known about the possible 
associations between HRQOL and demographic and 
clinical variables. To aid clinical decision-making, we 
conducted a systematic review and meta-analysis with 
the aim of evaluating the impact of psoriasis on HRQOL 
in patients aged between 4 and 18 years, and to explore 
the relationship between demographic and clinical vari-
ables and HRQOL in this population.
METHODS
The present study was conducted in accordance with Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) guidelines for reporting systematic reviews (24). The 
literature search, study selection, and data extraction were guided 
by an a priori-developed study protocol and conducted by 2 in-
dependent reviewers. Details are given in Appendix S11 (25–45).
RESULTS
Study selection
The study selection process is shown in Fig. 1. In a 
first screening, 2 reviewers (HR, TT) independently 
removed duplicates and reviewed titles and abstracts, 
resulting in 270 studies eligible for full-text screening. 
This included one additional study identified from the 
reference list of an existing systematic review and meta-
analysis (23), and 2 studies from reference lists of the 
included articles. Initially, the raters were uncertain or 
disagreed on 6 (2.2%) papers (inter-rater agreement: 
0.93; kappa statistic). After negotiation, 2 of these were 
included, along with one additional study identified in 
updated searches for 2016. The search and selection 
process resulted in a total of 17 papers, describing data 
for 20 groups of patients that could be subjected to 
meta-analysis, and 2 study samples that could only be 
reviewed qualitatively (46, 47). 
Fifteen authors of publications presenting results of 
mixed study populations (i.e. children and adults, and 
multiple skin diseases) or papers failing to provide the ne-
cessary values for effect size estimation were contacted. 
This resulted in the inclusion of 2 studies that had origi-
nally been excluded (33, 48). Furthermore, 10 authors 
of the included publications were contacted, requesting 
additional demographic and clinical information about 
study participants to be used in the moderator analyses. 
This was provided by 3 authors (33, 49, 50). Eleven pa-
pers (comprising data from 7 studies) were based on the 
same patient registry database and described potentially 
overlapping samples (49, 51–60). When contacted, the 
research group responsible for these studies was unable 
to specify the amount of overlap across studies. All 
but the most inclusive study (49) and a second study 
investigating patients of older age than in the remaining 
studies (60) were therefore excluded. The main reasons 
for exclusion were that papers only presented HRQOL 
data on pooled data from children and adults or from 1https://www.medicaljournals.se/acta/content/abstract/10.2340/00015555-2600
Fig. 1. Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) flow diagram of the study selection procedure.
Records identified through
database searches
(PubMed; Embase; Cinahl;
PsycINFO; Scopus (n=1,030)
Additional records identified
through other sources
(reference list and
clinicaltrials.gov (n=3)
Duplicates removed (n=469)
Records screened (n=564)
Records excluded (n=294)
Full-text articles assessed for eligibility (n=270)
Full-text articles excluded, with
reasons (n=254)
  1) Full-text article not retrievable (n=15)
  2) Non-English/German/Scandinavian language
      (n=5)
  3) Included adult patients only (n=96)
  4) Review/overview article (n=14)
  5) No HRQOL measurement (n=29)
  6) Presented HRQOL data from mixed samples
      only (n=75)
  7) HRQOL-measure not considered valid (n=2)
  8) Design/not representative sample (n=3)
  9) Insufficient data and no missing data provided
      (n=2)
10) Same or high risk of overlapping study
      population (n=13)
Studies included in qualitative (n=2)
and quantitative (n=15) synthesis
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patients with various types of skin disease, that they 
included adult patients only, or that they did not include 
HRQOL assessment (see Appendix S21). 
Study characteristics
The characteristics of the included studies are shown in 
Table SI1. The 17 studies investigated a total of 1,185 
children and adolescents between the age of 4 and 18 
years (mean age 12.8 years), with a majority of girls 
(57.9%). The included studies were conducted in 10 
different countries, with 16 papers being published in 
English and one in German. Two studies collected data 
from randomly selected patients from general population 
databases (46, 61). All the remaining studies recruited 
patients from dermatology outpatient clinics. Seven stu-
dies reported clinical disease severity, as assessed with 
the Psoriasis Area and Severity Index (PASI). In these 
studies, mean disease severity ranged from 2.7 to 21.1, 
and the mean PASI score across studies was 11.5, indi-
cating moderate to severe psoriasis. With the exception 
of 4 studies including only patients with plaque psoriasis 
(34, 35, 48, 62), most studies either did not specify or 
included the full range of clinical subtypes. 
Three studies were intervention studies and the remain-
ing 14 used observational designs. Of these, half of the 
studies focused on patients with psoriasis only (k (num-
ber of studies) = 7), while the remaining studies included 
comparative data from patients with other diseases (k = 5) 
or healthy controls (k = 2). The primary objectives in 
the observational studies were: (i) to assess HRQOL 
in paediatric psoriasis and/or examine the relationship 
between demographic, clinical or psychological variables 
and HRQOL; (ii) to test the psychometric performance 
of HRQOL instruments; and (iii) to compare HRQOL 
across different dermatological or chronic diseases.
HRQOL assessment was based on 4 validated ques-
tionnaires that were either generic or dermatology-
specific. The majority of studies (k = 12) were based 
on the Children’s Dermatological Life Quality Index 
(CDLQI) (25, 49, 50, 60–66) or the Dermatology Life 
Quality Index (DLQI) (48, 67) questionnaires, and one 
study utilized the Pediatric Quality of Life Inventory 
(PedsQL) (33). In addition, 2 studies included data from 
both CDLQI and PedsQL (34, 35). Lastly, Skindex-Teen 
(47) and KINDL-R (46) were used in one study each. 
The CDLQI and DLQI are child (4–16 years) and adult 
(>16 years) versions of the Dermatology Life Quality 
Index (25, 68). Both versions are the currently most 
used instruments measuring dermatology-related quality 
of life in their age group (68, 69). The CDLQI consists 
of 10 items, and is designed for children between 4 and 
16 years. It measures HRQOL across 6 subdomains; 
symptoms and feelings, leisure, school or holidays, 
personal relationships, sleep, and treatment. The total 
score on the CDLQI and DLQI range from 0 to 30, with 
higher scores indicating greater HRQOL impairment. 
The CDLQI has been translated and validated in more 
than 40 languages, with evidence of high internal con-
sistency, test–retest reliability, responsiveness to change, 
and significant correlations with other subjective and 
objective measures in paediatric dermatology samples 
(70). Although the majority of studies were based on the 
CDLQI, 2 studies used the adult parallel version (DLQI) 
(48, 67). Furthermore, 7 studies used the CDLQI in older 
adolescents (16–17-year-olds) for which the instrument 
has not been formally validated. 
PedsQL, the second most utilized questionnaire, is a 
generic instrument. The PedsQL was originally develo-
ped to study quality of life in children with cancer, and 
has subsequently been developed into a 23-item generic 
HRQOL-measure (71). The PedsQL measures patient’s 
perceptions of HRQOL, as defined in terms of the impact 
of disease and treatment on the individual’s physical, 
psychological, social functioning, and by disease/
treatment-specific symptoms. The PedsQL ranges from 
0 to 100, with higher scores indicating better HRQOL. 
The inventory includes age-appropriate versions for 
children aged 5–7, 8–12, and 13–18 in addition to a pa-
rent proxy version. The PedsQL core generic self-report 
scale has been translated into over 60 languages. It has 
demonstrated sufficient reliability, validity, sensitivity 
and responsiveness (72), but has not been specifically 
validated in patients with skin disease or psoriasis.
The Skindex-Teen and the KINDL-R were each used 
in one study. Skindex-Teen has been validated for use in 
adolescents (12–17 years) with skin disease (47). Its total 
score ranges from 0 to 84, with higher scores indicating 
greater HRQOL impairment. KINDL-R is a generic in-
strument with a total score ranging from 0 to 100, with 
higher scores denoting better HRQOL. The psychometric 
properties of KINDL-R have been established in a gene-
ral population of children and adolescents (73).
Methodological quality
Table SII1 summarizes the methodological quality of the 
included studies. The 2 raters agreed on 235 (92.2%) of 
the 255 individual study quality ratings, and the between-
rater total score correlation was 0.96 (p < 0.001). The 
mean total quality rating was 12.3 (standard deviation 
(SD) 3.3; range: 7–18). The majority of studies were cha-
racterized by small sample sizes, and only a few studies 
reported response rates (k = 7) or whether patients were 
in active treatment (k = 5). Additional metho dological 
concerns were that clinical disease severity was only 
reported in approximately two-thirds of studies (k = 10), 
and that several studies failed to report any clinical cha-
racteristics of their study population (k = 8). Six studies 
used HRQOL instruments or versions that distinguished 
between children and adolescents, and 4 studies divided 
their sample into different age groups and compared 
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HRQOL across these groups, providing information 
about possible effects of age.
Main analyses
The extracted data enabled 2 separate random-effects 
analyses to be conducted; one based on dermatology-
specific (CDLQI and DLQI) and one on generic (PedsQL) 
instruments. Results of the main analyses are shown in 
Fig. 2. Mean dermatology-specific HRQOL impairment 
was based on 14 studies (including 15 independent 
groups), yielding an aggregated sample of 1,012 patients. 
Results showed a weighted mean CDLQI/DLQI score 
across studies of 7.7 (95% confidence interval (95% CI) 
6.67–8.73), indicating moderate HRQOL impairment 
(36), with a 95% prediction interval from 3.6 to 11.8. 
Study heterogeneity was large (I2 = 88.4). The PedsQL 
instrument was used in 3 studies (including 5 independent 
groups) and a total of 370 patients. The weighted mean 
PedsQL score was 74.5 (95% CI 72.82–76.25), with 
the prediction interval ranging from 71.8 to 77.3. There 
were no indications of heterogeneity of results (I2) for 
the studies using the PedsQL. Possible publication bias 
was inspected visually by means of funnel plots, and 
statistically using Eggers’ test. Neither analysis suggested 
publication bias, as estimates appeared symmetrically 
distributed in the funnel plot, and Eggers’ tests did not 
reach statistical significance. The Skindex-Teen and 
KINDL-R were only used in one study each, and hence 
meta-analysis was not possible for these instruments (see 
Table SI1 for mean scores).
Moderator-analyses
As seen in Table I, meta-regression revealed several 
moderating effects of various study characteristics on the 
impact of psoriasis on HRQOL. As preliminary analyses 
revealed high correlations (r > 0.70) between some of the 
demographic and clinical variables to be explored, we 
adjusted for these variables by entering them as covariates 
in the relevant regression models. Due to the limited sta-
tistical power of these preliminary analyses, we adjusted 
for such relationships regardless of whether the correlation 
reached statistical significance.
In searching for possible moderating influences of de-
mographic variables, meta-regression analyses revealed 
that the percentage of girls in the study samples (adjusted 
for region, as r: –0.93; p < 0.001) was the only statistically 
significant moderator of HRQOL, with study samples 
with a higher proportion of girls having lower (better) 
mean total scores on the CDLQI/DLQI. Age was not a 
statistically significant moderator of HRQOL. Regarding 
the clinical variables, age at onset (adjusted for disease 
severity, r: 0.71, p = 0.178) statistically significantly 
Table I. Results of meta-regression analyses
Variables K Βa 95% CI p-value
Mean total score on the Dermatology Life Quality Index (CDLQI and DLQI)
  Percentage girls (unadjusted) 12 –0.14 –0.24 to –0.04 0.005** 
    Adjusted for region 10 –0.19 –0.29 to –0.08 < 0.001***
  Age 11 0.05 –0.71–0.81 0.896
  Disease severity (unadjusted) 7 0.26   0.14–0.38 < 0.001***
    Adjusted for age at onset 5 0.15 –0.01–0.31 0.063c
  Age at onset (unadjusted) 6 0.83 0.37–1.30 < 0.001***
    Adjusted for disease severity 5 0.50 0.03–0.31 0.041*
  Duration 7 0.04 –0.49–0.11 0.350
  Region (unadjusted) 13 0.83 –1.56–3.22 0.495
    Adjusted for percentage girls 10 –6.66 –15.20–1.88 0.126
  Study quality 15 0.28 0.01–0.55 0.043*
Mean total score on the PedsQL: Pedatric Quality of Life Inventory (PedsQL)
  Percentage girls 5 –0.12 –0.40–0.16 0.410
  Age 5 0.01 –1.39–1.41 0.986
  Severityb 5 0.09 –0.33–0.50 0.680
  Duration 5 0.05 –0.04–0.13 0.289
  Region 4 –1.45 –6.08–3.17 0.538
*p < 0.05; **p < 0.01, ***p < 0.001.
aMixed effects regression: unrestricted maximum likelihood. bNot adjusted due to 
insufficient number of studies. cNear-significant (p < 0.10). K: number of studies; 
CI: confidence interval.
Fig. 2. Forest plot of weighted means health-related quality of life (HRQOL) in paediatric psoriasis by instrument.
0,00 5,00 10,00 15,00 20,00 25,00 30,00 
Very large No Small Moderate Extremely  large  
Balci et al., 2007 (63) 7.67 4.41 10.93 6
Beattie & Lewis-Jones, 2006 (64) 9.17 6.32 12.02 29
Chang et al., 2010 (67) 7.50 6.55 8.45 180
de Jager et al., 2011 (61) 2.90 1.43 4.37 15
Gånemo et al., 2011 (50) 5.05 3.54 6.56 42
van Geel et al., 2016 (60) 6.61 5.11 8.11 56
Khawaja et al., 2015 (48) 9.49 3.14 15.84 8
Landells et al., 2015 (62) 9.60 8.33 10.87 101
Langley et al., 2011a (34) 8.90 7.72 10.08 100
Langley et al., 2011b (34) 10.00 8.76 11.24 102
Lewis-Jones & Finlay, 1995 (25) 5.40 3.44 7.36 25
Manzoni et al., 2012 (65) 7.90 6.65 9.15 25
Matusiewicz et al., 2013 (66) 7.60 6.85 8.35 84
Oostveen et al., 2012 (49) 7.50 6.62 8.38 125
Papp et al., 2014a (35) 11.30 10.06 12.54 114
Combined (random effects model) 7.70 6.67 8.73 1012
Prediction interval (I 2 = 88.3 %, p < 0.001, 2 = 3.29) 3.62 11.78
Study name
Mean Lower limit Upper limit Total n
Statistics for each study
Effect on Health-Related Quality of Life (severity stratification):
Health-related quality of life in pediatric psoriasis measured by Children's Dermatology Life  Quality Index (13 studies) and Dermatology Life Quality  Index (2 studies) 
Health-related quality of life in pediatric psoriasis measured by the Pediatric Life Quality Inventory
Bilgic et al., 2010a (33) 72.83 67.31 78.35 22
Bilgic et al., 2010b (33) 75.33 69.59 81.07 26
Langley et al., 2011c (34) 74.80 71.38 78.22 104
Langey et al., 2011d (34) 75.10 72.85 79.35 104
Papp et al., 2014b (35) 73.10 69.90 76.30 114
Combined (random effects model) 74.53 72.82 76.25 370
Prediction interval (I2 = 0.0 %, p < .712, 2 = 0.0) 71.75 77.31
Study name Mean Lower limit Upper limit Total n
Statistics for each study
60 65 70 75   80    85     90      95      100 
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moderated HRQOL, with higher age at onset being as-
sociated with higher (worse) CDLQI/DLQI scores. In 
addition, psoriasis severity (adjusted for age at onset) 
emerged as a near-significant moderator of HRQOL, 
while duration of psoriasis did not. Finally, study quality 
also statistically significantly moderated the results, with 
higher study quality scores being associated with grea-
ter HRQOL impairment. For studies using the PedsQL 
instrument, the meta-regression analyses did not reveal 
any significant determinants of HRQOL. All moderator 
analyses regarding PedsQL data were based on either 4 or 
5 studies, and hence suffered from low statistical power. 
DISCUSSION
Primary findings
This systematic review and meta-analysis provides an 
overview of HRQOL in 1,185 children and adolescents 
with psoriasis from 10 different countries. The results 
of the meta-analyses revealed weighted mean total 
scores of 7.7 (95% CI 6.67–8.73) for studies using 
CLDQI and DLQI, and 74.5 (95% CI 72.82–76.25) for 
PedsQL, indicating a moderate effect on HRQOL (36). 
A sensitivity analysis excluding the two DLQI-studies 
from the CDLQI/DLQI analysis, revealed an unchanged 
weighted mean score. The PedsQL is a generic instru-
ment, and, while published data from normative samples 
are available online, there are currently no data on the 
interpretability of PedsQL scores in paediatric psoriasis. 
Our main result regarding the impact of paediatric 
psoriasis on HRQOL as measured by the CDLQI/DLQI 
is consistent with findings from a previously published 
meta-analysis (23), which combined data from 6 studies 
on 279 patients with psoriasis. However, the authors 
noted that the confidence intervals were particularly 
wide for the psoriasis subgroup, and that the estimate 
might be too conservative. They suggested that psoriasis-
related HRQOL might be similar, or even worse, than 
the moderate impairment reported by the atopic eczema 
subgroup. In the present study, to assist the interpretation 
of results, prediction intervals were calculated, showing 
that mean CDLQI/DLQI scores in paediatric psoriasis 
populations are expected to fall within the range between 
3.6 and 11.8. In clinical terms, this relatively broad inter-
val ranges from a small to moderate effect on HRQOL, 
and thus does not support Olsen et al.’s interpretation 
that psoriasis might be associated with greater HRQOL 
impairment than atopic eczema (23).
Moderators
To our knowledge, the present meta-analysis is the first 
to summarize findings on HRQOL across studies in pa-
ediatric psoriasis, taking the influence of demographic 
and clinical variables into account. The relevance of 
searching for potential moderators was highlighted by the 
large heterogeneity of studies using the CDLQI/DLQI. 
Our moderator analyses revealed statistically significant 
effects of sex, age at onset, and study quality, but not of 
age, psoriasis duration, or geographical region. Clinical 
disease severity (PASI) was a near-significant moderator 
of HRQOL. However, because several of the included 
studies failed to report important demographic and 
clinical characteristics of their study participants, these 
results should be interpreted with caution. 
Although not directly comparable to our systematic 
review, due to the sample consisting mainly of adult pa-
tients (mean age in studies ranged from 43 to 56 years), 
de Korte et al.’s (22) systematic review examined rela-
tionships between background variables and HRQOL in 
psoriasis. Based on findings from 8 studies, the authors 
concluded that HRQOL seemed to be unrelated to sex, 
and that there was a tendency for higher age to be as-
sociated with slightly higher levels of overall quality of 
life. Furthermore, more severe psoriasis appeared to be 
associated with more impaired HRQOL. However, the 
authors noted that the included studies were characte-
rized by a high degree of heterogeneity. A number of 
methodological shortcomings furthermore complicated 
the synthesis of study results, which was possible only 
for age, sex and disease severity (22). In contrast to de 
Korte et al.’s findings, we did not find any effects of age 
or disease duration on HRQOL, but only of age at onset. 
Several interpretations of our findings appear relevant. 
First, the majority of studies included in our review 
relied on data from the CDLQI, which is designed for 
use in children aged between 4 and 16 years. However, 
many studies used this instrument in adolescents up to 18 
years, or used the adult version in adolescents younger 
than 16 years. Considering the differences in context 
and social life of children, adolescents, and adults (13, 
74), data from a questionnaire used with both immature 
5-year-olds and maturing adolescents 15–17 years old 
would, perhaps, be less likely to reveal age effects.
In contrast, age at onset was statistically significantly 
associated with HRQOL, with paediatric patients di-
agnosed at an older age experiencing higher HRQOL 
impairment than children with early debut. This finding 
could possibly be explained by developmental factors. 
Compared with younger children, adolescents spend a 
considerable proportion of their time with friends, gain-
ing independence from their families, and feeling accep-
ted by peers is especially important (74). Coping with a 
newly developed skin disease and its significant cosmetic 
impact could be particularly difficult in a period of life 
when social and cultural pressures stress homogeneity in 
appearance as desirable. In line with this interpretation, 
Perrott et al.’s (75) study on stigmatization and quality 
of life in psoriasis, led the authors to advocate the need 
for clinicians to pay particular attention to children and 
adolescents who develop psoriasis during the critical 
periods of peer comparison and identity formation. 
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As adolescents with newly developed psoriasis may 
not have had sufficient time to adapt to their altered 
appearance, this could cause impairments in a broad 
range of aspects of HRQOL. Indeed, previous quali-
tative research has documented disrupted body image, 
decrease in self-confidence, social isolation, and other 
adverse effects on psychosocial functioning in adolescent 
psoriasis (12, 13). Hence, a possible explanation for our 
findings could be that the CDLQI instrument is not suf-
ficiently age-sensitive, as it does not include important 
adolescent-specific aspects of HRQOL, such as sexual 
or intimacy difficulties or concerns relating to finding 
romantic partners and future aspirations in general (13). 
Our results could indicate that the difficulties associa-
ted with adolescent onset of psoriasis are so profound 
that even instruments with poor sensitivity towards 
adolescent-specific issues are able to detect some of these 
issues, leading to a significant effect of age at onset, but 
not of age per se.
If one ignores the possibility that HRQOL in psoriasis 
may be qualitatively different in children and adoles-
cents, it seems reasonable to assume that longer disease 
duration would lead to improved coping skills and 
adaption to the disease over time. Based on this assump-
tion, our finding that disease duration did not moderate 
HRQOL could appear surprising. It should be noted, 
however, that the moderator analyses of duration and 
age at onset may have been insufficiently powered (k = 6 
and 7, respectively), and thus may be less robust than the 
non-significant age effects (k = 11). The explanation that 
the instrument is not sufficiently age-sensitive to detect 
age-related differences thus appears most convincing. 
Sex was also identified as a moderator of HRQOL, 
with a higher percentage of girls in the samples being 
associated with less impairment. This was a relatively 
surprising finding, as the general literature on HRQOL 
in chronic disease often suggests either mixed findings 
(29) or greater impairment in female patients (76, 77). 
One explanation could be that the CDLQI/CLDQI-
instruments are more sensitive to difficulties experienced 
by boys than those experienced by girls. To the best of 
our knowledge, the CDLQI has not yet been psycho-
metrically evaluated with regard to differential item 
functioning (DIF), which tests for the possibility of 
items being biased towards certain subgroups, e.g. girls 
and boys (78). Although the items in the CDLQI and the 
adult version (DLQI) are not identical, it is interesting 
that item-response analysis of the DLQI caused authors 
to caution the use of this instrument to detect sex dif-
ferences, due to violation of this assumption (79). Alter-
natively, other methodological issues may be responsible 
for our findings. Although we attempted to adjust for 
possible confounding variables in the meta-regression 
analyses, several studies failed to report numerical values 
concerning clinical disease severity in patients. In fact, 2 
of the 3 studies with the greatest proportion of girls did 
not include the information necessary to be included in 
the preliminary correlation analysis testing for possible 
confounders. As clinical disease severity was established 
as a near-significant moderator of HRQOL, the lack of 
these data could be a possible explanation for our finding 
that samples with higher numbers of girls had less im-
paired HRQOL. Further studies are needed to evaluate 
sex differences in paediatric psoriasis HRQOL.
Although based on a relatively poorly powered 
moderation analysis (k = 5), our results also revealed 
a near-significant effect of clinical disease severity on 
HRQOL. This result is in line with the above-cited fin-
dings of de Korte et al. (22) that more severe psoriasis 
was associated with greater impairment in HRQOL. 
Furthermore, research within adult patients has shown 
positive correlations between PASI and DLQI scores in 
patients with moderate-to-severe psoriasis undergoing 
treatment (80). While only 3 studies in our systematic 
review included pre- and post-treatment assessments, 
their results all indicated reduced disease severity 
combined with positive change-scores on the CDLQI 
across different treatment regimens (34, 49, 62). As 
the assumption that this relationship is not necessarily 
linear has been broadly advocated (6), further research 
is needed to establish the association between clinical 
disease severity and HRQOL.
When exploring associations with methodological qua-
lity, we found greater HRQOL impairment in studies of 
higher quality. All intervention studies scored relatively 
high on study quality. As these studies included only 
patients within the moderate-to-severe psoriasis range, 
and disease severity was a near-significant moderator 
of HRQOL, this could explain the moderating effect of 
study quality as an indirect effect of variation in study 
designs. When exploring differences between studies 
conducted in Western vs. other countries, we found no 
moderating effect.
Strengths and limitations
This is the first study to summarize the impact of pa-
ediatric psoriasis on HRQOL and to explore the mo-
derating effects of demographic and clinical variables. 
Our study has several strengths. First, it was based on a 
comprehensive search and conducted in accordance with 
recommended guidelines (24). Secondly, to limit the in-
fluence of publication bias, we also searched for material 
from the “grey literature”, e.g. conference abstracts and 
unpublished studies. Thirdly, because of the scarcity of 
published data on patients with paediatric psoriasis, we 
made a great effort to collect non-published data from 
the identified studies.
Some study limitations should also be mentioned. 
First, we found high heterogeneity of studies using the 
CDLQI/DLQI, suggesting systematic between-study 
variance rather than variation due to random sampling 
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error. Statistical heterogeneity should not necessarily be 
interpreted as a limitation or flaw, either in the individual 
studies or in the meta-analytic process, but indicates that 
the weighted mean should be viewed as an estimate of 
the mean expected HRQOL impairment across a wide 
range of different groups and settings.
A second limitation could be that, due to the limited 
number of studies, we included studies using the CDLQI 
in adolescents of 16–17 years of age, as well as studies 
using the DLQI in adolescents. However, neither the 
CDLQI nor the DLQI instrument is designed specifically 
for 16- and 17-year-olds with skin disease (60), and stu-
dies of patients with psoriasis who were younger than 
18 years usually combine data from children and adoles-
cents. Van Geel et al. (60) compared scores on the child 
(CDLQI) and adult (DLQI) version of the instrument in 
16–17-year-old patients with psoriasis. Although a high 
correlation (r = 0.90) was found between total scores on 
the 2 instruments, the mean total score on the DLQI was 
statistically significantly lower than the mean CDLQI 
score. The difference between scores across the versions 
was driven primarily by adolescents scoring lower on 
the DLQI-item concerning sexual difficulties (“Over the 
last week, how much has your skin caused any sexual 
difficulties?”), and higher on the corresponding item 
addressing sleep problems in the CDLQI-version. The 
wording of the question in the DLQI-version refers to 
sexual difficulties over the previous week only, and does 
not appear to be particularly appropriate for adolescents. 
Previously mentioned research indicate that they might 
have qualitatively different experiences than adults when 
it comes to sexuality and intimate relationships (13, 74), 
and also less frequent sexual experiences.
Thirdly, as most studies report no sex difference in 
the prevalence of paediatric psoriasis (81), our results 
could have been influenced by the finding that girls 
were over-represented in the studies included in both 
random-effects models. However, when comparing the 
un-weighted mean values for CDLQI/DLQI (7.77) and 
PedsQL (74.43) with the random effects weighted av-
erages (7.70 and 74.53, respectively), the results differed 
only marginally, indicating that the sex skewness is un-
likely to pose a problem for our interpretation of results. 
Fourthly, most studies in our systematic review investi-
gated patients recruited from secondary care settings, 
and hence the samples might not be representative of the 
general population of paediatric patients with psoriasis. 
HRQOL in children and adolescents not seeking help for 
their psoriasis-related skin problem may be different from 
the HRQOL of patients undergoing treatment. 
Lastly, the studies included in our meta-analyses used 
generic and dermatology-specific instruments only. Since 
disease-specific measures, e.g. psoriasis-specific instru-
ments, are acknowledged to be more sensitive towards 
disease-specific aspects, this may have resulted in failure 
to detect potentially true effects.
Conclusion
The present meta-analysis suggests that children and 
adolescents with psoriasis experience a moderate im-
pairment in HRQOL. The wide prediction interval for 
studies using the CDLQI/DLQI instrument, combined 
with the results of our moderation analyses, highlight the 
importance of measuring HRQOL to inform treatment 
planning, and the need for future studies to explore po-
tential determinants of HRQOL.
To improve our knowledge about psoriasis-related 
HRQOL in children and adolescents, future studies 
should: (i) take care to provide separate data for different 
age- and disease-groups; (ii) collect and report relevant 
demographic (age; sex) and clinical (disease severity; 
subtype; age at onset; duration; treatment status) infor-
mation on study participants, and (iii) include validated 
measures of HRQOL in intervention studies. 
Furthermore, we were unable to identify any psoriasis-
specific HRQOL instrument for children and adolescents, 
except for 1 questionnaire designed for paediatric patients 
with scalp psoriasis (57). Moreover, closer examination 
of the included instruments revealed that patients with 
psoriasis were often highly underrepresented or absent in 
the validation studies of the HRQOL instruments utilized 
for this population (25, 47). This raises further concerns 
about the applicability of existing HRQOL instruments 
in paediatric psoriasis. 
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